Workshop 1: Keeping PACE™ in the Timely Detection and Neuropathological Diagnosis of Alzheimer's Disease: Practical Strategies for Integrating Biomarkers Into Diagnostic Workflows

Monday, July 29
12:30 – 1:45 p.m.
Philadelphia Marriott Downtown (Grand Ballroom A-F)

Work with the experts and your peers to keep PACE with recent advances in Alzheimer’s disease (AD) biomarker testing to Propel Alzheimer’s Care Enhancement!

AD is rarely diagnosed in its early stages outside of clinical trials, even though the benefits of early detection and diagnosis are well established. The first session of this two-part Train-the-Trainer MasterClass Workshop will focus on significant advances in the identification and validation of biomarkers for AD that can aid in early diagnosis, facilitate patient selection for treatment, and monitor therapeutic response.

In this lunchtime program, experts will review the disease burden of AD and the current diagnostic guidelines, before discussing validated and emerging AD biomarkers. Illustrative patient case examples will highlight the practical considerations behind the science, and small and large group discussions of patient cases will facilitate the translation of learning to application in daily practice.

Join PeerView for one or both CME/ABIM MOC/NCPD/AAPA sessions!

This activity is supported by an educational grant from Lilly.

For more information and to register for this two-part workshop series, please visit: PeerView.com/PACE24-Live.

Workshop 2: Keeping PACE™ in the Management of Alzheimer's Disease: Precision Strategies for Safely Utilizing Disease-Modifying Therapies in Clinical Practice

Monday, July 29
6 – 7:30 p.m.
Philadelphia Marriott Downtown (Grand Ballroom A-F)

Work with the experts and your peers to keep PACE with new treatments for Alzheimer’s disease (AD) to Propel Alzheimer’s Care Enhancement!

The second session of our Train-the-Trainer MasterClass Workshop will center around safely integrating disease-modifying therapies (DMTs) into treatment for your patients with AD. Recent breakthroughs with amyloid-targeting therapies (ATTs) have opened the door to the possibility of reductions in disease progression and improved patient outcomes.

Our panel will reconvene to review the latest developments in AD treatment — including the efficacy and safety data in early symptomatic AD — as well as strategies for integrating ATTs effectively and safely into clinical practice. The discussion will then focus on recommended guidelines for monitoring and managing amyloid-related imaging abnormalities (ARIA) in patients undergoing treatment with ATTs. Patient cases and small and large group discussions will once again enable participants to engage with experts and learn from one another.

Join PeerView for one or both CME/ABIM MOC/NCPD/AAPA sessions!

This activity is supported by an educational grant from Lilly.

For more information and to register for this two-part workshop series, please visit: PeerView.com/PACE24-Live.

Advances in Imaging Biomarkers in Alzheimer’s Disease Research

Monday, July 29
6 – 7:30 p.m.
Philadelphia Marriott Downtown (Grand Ballroom G-L)

Join us for a presentation from neuroimaging experts who will discuss recent developments in the use of positron emission tomography (PET) biomarkers in Alzheimer’s disease clinical research.

Sponsored by: Lantheus Cerveau

Explore a New Therapy for Early Symptomatic Alzheimer’s Disease

Tuesday, July 30
6:15 – 7:45 a.m.
Philadelphia Marriott Downtown (Grand Ballroom A-F)

Listen to a live presentation about the recent efficacy and safety findings of a treatment option for patients with early symptomatic Alzheimer’s disease.

This program is sponsored by, and presented on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit. PP-DN-US-0044 07/2024 ©Lilly USA, LLC 2024. All rights reserved.

Sponsored by: Lilly

The Future of Care for Alzheimer’s Disease: Breakthroughs and Beyond

Tuesday, July 30
12:30 – 1:45 p.m.
Philadelphia Marriott Downtown (Grand Ballroom G-L)

At AAIC^® 2024, we are thrilled to bring together a panel of leading experts from clinical practice, research, and a patient organization for the symposium, The future of care for Alzheimer’s disease: breakthroughs and beyond. Professor Marwan Sabbagh will chair the expert faculty panel in exploring recent diagnostic and therapeutic developments in the Alzheimer’s disease (AD) landscape.

They will discuss advancements in blood-based biomarkers, the importance of neuroinflammation in Alzheimer’s disease (AD) pathology, and the next generation of potential therapies for AD. They will also explore how these recent developments impact the lives of people with AD, their care partners and society, and how they can be translated into clinical practice.

Throughout the meeting, the faculty will have opportunities to answer questions from the audience, as well as share key learnings from their professional experience.

Sponsored by: Novo Nordisk

40 Years Plus 1: Discussing How to Operationalize Eisai Inc. and Biogen’s Anti-Amyloid Option for Early Alzheimer’s Disease

Tuesday, July 30
6 – 7:30 p.m.
Philadelphia Marriott Downtown (Grand Ballroom A-F)

One year after traditional FDA approval of an anti-amyloid treatment for Alzheimer’s disease, a multidisciplinary panel will provide an update on data supporting its clinical results and share real patient cases depicting approaches to integrate this treatment option into a clinical workflow, including collaboration with other specialties.

Sponsored by: Eisai

Beyond Memory Loss: Recent Advances in the Management of Agitation in Alzheimer’s Dementia

Wednesday, July 31
12:30 – 1:45 p.m.
Philadelphia Marriott Downtown (Grand Ballroom A-F)

Agitation is a common neuropsychiatric symptom in patients with Alzheimer’s dementia and may manifest as a number of distinct behaviors encompassing excessive motor activity, verbal aggression, and/or physical aggression. Agitation worsens the impact of an already devastating and burdensome disease for patients and is associated with increased caregiver burden and higher rates of patient institutionalization. This symposium will explore the breadth of agitation behaviors and their impact, review diagnostic and management considerations, and discuss nonpharmacologic and pharmacologic treatment options.

Sponsored by: Lundbeck and Otsuka

Ask the Experts: Navigating Implementation of Alzheimer’s Disease Patient Care in a Dynamic Landscape

Wednesday, July 31
6 – 7:30 p.m.
Philadelphia Marriott Downtown (Grand Ballroom G-L)

With the advent of emerging therapies for patients with early Alzheimer’s disease (AD), it is now more important than ever to have efficiency along the patient care pathway. Take this time with us to interact with experts as you navigate steps along the AD patient care pathway. This event will give you an opportunity to learn from experts on topics including:

1. Partnering for Progress: Defining a Patient-Centered Paradigm for Advances in Alzheimer's Disease
2. Enhancing Alzheimer’s Disease Care: Primary Care at the Forefront in the Evolving Patient Journey
3. Alzheimer's Disease and ARIA: Clinical Guidance for Alzheimer's Disease Treatment Monitoring
4. The Clinical Use of Approved Biomarkers for Alzheimer's Disease Diagnosis and Treatment Considerations
5. Expert Insights to Increase Preparedness for Implementation of Emerging Alzheimer’s Disease Treatments

This session aims to provide 5 small session-experiences and a unique opportunity for you to engage and discuss with the experts on these topics.

Sponsored by: Eisai